Elamipretide, a Mitochondrial-Targeted Drug, in the Treatment of Dry AMD

Time: 3:40 pm
day: Day One


  • Elamipretide preclinical data showed reversal of AMD pathophysiology & improvement of vision
  • A phase 1 open label safety study of elamipretide in patients with dry AMD showed improvements in multiple measures of vision
  • A phase 2, randomized, double-masked, placebo-controlled clinical study of elamipreide in patients with dry AMD is on-going.